We are delighted to share that, as of 2 August 2024, SYDRA is a member of NVIDIA Inception — NVIDIA's program for startups building with AI.
AI is not an add-on to SYDRA's work; it is part of the core discovery architecture. Joining the Inception community connects our team with technical resources, training, and a global ecosystem of founders, experts, and investors as we continue advancing our AI-assisted, phenotype-first drug-discovery platform.
We are proud to join this community of ambitious AI-native companies and look forward to learning, building, and contributing alongside it.
For SYDRA, the goal remains clear: turning lifespan-extending HITs into medicines for age-related diseases.